<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631499</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-HE-TACE</org_study_id>
    <nct_id>NCT02631499</nct_id>
  </id_info>
  <brief_title>Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation</brief_title>
  <official_title>Post-hepatectomy Adjuvant Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Preoperative CTC Level ≥2: a Multicenter Randomized Controlled Trial in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johnson &amp; Johnson Medical, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to prospectively evaluate whether post-hepatectomy adjuvant
      transcatheter arterial chemoembolization (TACE) is effective in reducing early recurrence in
      HCC patients with preoperative CTC ≥2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, and
      associated morbidity and mortality rates have escalated in recent years. Despite improvements
      in surveillance and clinical treatment strategies, the prognosis of HCC remains very poor due
      to high incidence of recurrence and metastasis. Recent clinical studies have provided
      evidence that circulating tumor cell (CTC) may directly participate in the metastasis cascade
      in various types of malignancies. The investigators previous data indicated that HCC patients
      with preoperative CTC levels ≥2 suffered significantly earlier recurrence (within 1 year)
      than patients with lower levels. However, the benefits of postoperative adjuvant therapies in
      preventing early recurrence in patients with preoperative CTC ≥2 remain to be elucidated.
      Transarterial chemoembolisation (TACE) is an effective palliative treatment for HCC. The
      investigators design a randomised controlled trial evaluating the efficacy of using TACE
      after hepatectomy to reduce early recurrence rates in HCC patients with preoperative CTC
      level ≥2.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early recurrence rates</measure>
    <time_frame>1 year after hepatectomy</time_frame>
    <description>Early recurrence was defined as any type of recurrence diagnosed within 1 year after hepatectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>OS was defined as the interval from date of HCC resection to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Neoplastic Cells, Circulating</condition>
  <arm_group>
    <arm_group_label>Adjuvant TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TACE will be performed 4-6 weeks after hepatectomy in patients with preoperative CTC ≥2 Epirubicin, lipiodol and gelatin sponge articles are used in TACE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no interventions were assigned after hepatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.</description>
    <arm_group_label>Adjuvant TACE</arm_group_label>
    <other_name>Transcatheter Arterial Chemoembolization</other_name>
    <other_name>Chemoembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Epirubicin is a chemotherapy drug used in TACE</description>
    <arm_group_label>Adjuvant TACE</arm_group_label>
    <other_name>EADM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipiodol</intervention_name>
    <description>lipiodol is a kind of embolization material used in TACE</description>
    <arm_group_label>Adjuvant TACE</arm_group_label>
    <other_name>Ultra-fluid lipiodol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCC patients received curative hepatectomy with negative resection margin

          -  Age from 18 to 75

          -  Child-Pugh class A

          -  ASA class I to II

          -  ECOG performance status Grade 0 or 1

          -  Preoperative CTC level ≥2 per 7.5 ml peripheral blood

          -  No residual tumor revealed by hepatic arterial angiography 4-6 weeks after hepatectomy

        Exclusion Criteria:

          -  Patients diagnosed with other types of malignancies besides HCC

          -  Patients receiving concomitant local ablation or previous TACE

          -  Main portal vein tumor thrombus extraction during hepatectomy

          -  Hepatic arterial angiography before adjuvant TACE treatment reveals residual tumors.

          -  Presence of extra-hepatic or lymphatic metastasis

          -  Impaired liver function with either clinically detected ascites, hepatic
             encephalopathy, serum albumin &lt; 25g/L or bilirubin &gt; 50micromol/L

          -  Renal impairment with creatinine &gt; 200micromol/L

          -  Severe concurrent medical illness persisting &gt; 6 weeks after hepatectomy

          -  History of other cancer

          -  Hepatic artery anomaly making TACE not possible

          -  Allergy to 5-Fluorouracil, Epirubicin or lipiodol

          -  Pregnant woman

          -  Informed consent not available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Fan, MD &amp; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin-Rong Yang, MD &amp; PhD</last_name>
    <phone>008618616881978</phone>
    <email>yang.xinrong@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yun-Fan Sun, MD &amp; PhD</last_name>
    <phone>008613162601787</phone>
    <email>yunfan_sun@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nantong Tumor Hospital</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Soochow</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Affliated with Shanghai Jiao Tong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J, Fan J. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013 Apr;57(4):1458-68. doi: 10.1002/hep.26151. Epub 2013 Mar 4.</citation>
    <PMID>23175471</PMID>
  </reference>
  <reference>
    <citation>Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009 Oct;135(10):1437-45. doi: 10.1007/s00432-009-0588-2. Epub 2009 May 1.</citation>
    <PMID>19408012</PMID>
  </reference>
  <reference>
    <citation>Ren ZG, Lin ZY, Xia JL, Ye SL, Ma ZC, Ye QH, Qin LX, Wu ZQ, Fan J, Tang ZY. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol. 2004 Oct 1;10(19):2791-4.</citation>
    <PMID>15334671</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>December 20, 2015</last_update_submitted>
  <last_update_submitted_qc>December 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jia Fan</investigator_full_name>
    <investigator_title>President of Shanghai Zhongshan Hospital</investigator_title>
  </responsible_party>
  <keyword>Circulating Tumor Cells</keyword>
  <keyword>Hepatoectomy</keyword>
  <keyword>TACE</keyword>
  <keyword>prognosis</keyword>
  <keyword>relapse</keyword>
  <keyword>Chemoembolization, Therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

